DBV Technologies S.A. (DBV.PA)
EUR 1.33
(3.59%)
EUR 1.33
(3.59%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | - EUR | -100.0% |
| 2022 | 4.8 Million USD | -15.91% |
| 2021 | 5.7 Million USD | 0.0% |
| 2020 | - EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | -100.0% |
| 2015 | 220.84 Thousand EUR | -13.83% |
| 2014 | 256.28 Thousand EUR | 2.09% |
| 2013 | 251.04 Thousand EUR | 8.87% |
| 2012 | 230.59 Thousand EUR | 41.14% |
| 2011 | 163.37 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.4 Million USD | -84.15% |
| 2024 Q2 | 1.16 Million USD | -17.48% |
| 2023 Q1 | 2.19 Million USD | 268.25% |
| 2023 FY | - EUR | -100.0% |
| 2023 Q4 | 8.87 Million USD | 269.79% |
| 2023 Q3 | 2.4 Million USD | 4.9% |
| 2023 Q2 | 2.28 Million USD | 4.28% |
| 2022 Q3 | 2.07 Million USD | 35.64% |
| 2022 Q4 | -1.3 Million USD | -162.87% |
| 2022 Q1 | 2.54 Million USD | -55.4% |
| 2022 Q2 | 1.52 Million USD | -39.95% |
| 2022 FY | 4.8 Million USD | -15.91% |
| 2021 Q1 | 2.94 Million USD | 342.66% |
| 2021 Q2 | -1.48 Million USD | -150.6% |
| 2021 Q3 | 1.32 Million USD | 188.91% |
| 2021 Q4 | 5.7 Million USD | 331.44% |
| 2021 FY | 5.7 Million USD | 0.0% |
| 2020 Q1 | 4.72 Million USD | 182.22% |
| 2020 Q3 | 4.15 Million USD | 15.18% |
| 2020 FY | - EUR | 0.0% |
| 2020 Q4 | -1.21 Million USD | -129.15% |
| 2020 Q2 | 3.61 Million USD | -23.52% |
| 2019 FY | - EUR | 0.0% |
| 2019 Q4 | 1.67 Million EUR | -33.46% |
| 2019 Q1 | 3.34 Million USD | -6.75% |
| 2019 Q2 | 3.39 Million USD | 1.38% |
| 2019 Q3 | 2.51 Million EUR | -25.98% |
| 2018 FY | - EUR | 0.0% |
| 2018 Q4 | 3.59 Million EUR | 40.28% |
| 2018 Q3 | 2.56 Million EUR | -24.94% |
| 2018 Q2 | 3.41 Million USD | -5.21% |
| 2018 Q1 | 3.59 Million USD | 87.39% |
| 2017 Q2 | 3.65 Million USD | 7.06% |
| 2017 Q3 | 1.89 Million USD | -48.22% |
| 2017 Q4 | 1.92 Million USD | 1.51% |
| 2017 FY | - EUR | 0.0% |
| 2017 Q1 | 3.41 Million USD | 109.64% |
| 2016 Q1 | 2.52 Million USD | 55.3% |
| 2016 FY | - EUR | -100.0% |
| 2016 Q4 | 1.62 Million USD | -6.3% |
| 2016 Q3 | 1.73 Million USD | -29.47% |
| 2016 Q2 | 2.46 Million USD | -2.49% |
| 2015 Q1 | 1.56 Million USD | 22.83% |
| 2015 FY | 220.84 Thousand EUR | -13.83% |
| 2015 Q4 | 1.62 Million USD | -2.68% |
| 2015 Q3 | 1.67 Million USD | -12.55% |
| 2015 Q2 | 1.91 Million USD | 22.42% |
| 2014 Q4 | 1.27 Million USD | -4.09% |
| 2014 FY | 256.28 Thousand EUR | 2.09% |
| 2014 Q1 | 1.76 Million USD | 2.67% |
| 2014 Q2 | 1.89 Million USD | 7.64% |
| 2014 Q3 | 1.32 Million USD | -30.02% |
| 2013 Q2 | 868.38 Thousand USD | 1.46% |
| 2013 Q3 | 1.68 Million USD | 94.07% |
| 2013 Q4 | 1.71 Million USD | 1.72% |
| 2013 FY | 251.04 Thousand EUR | 8.87% |
| 2013 Q1 | 855.92 Thousand USD | -11.1% |
| 2012 Q3 | 937.84 Thousand USD | 0.0% |
| 2012 FY | 230.59 Thousand EUR | 41.14% |
| 2012 Q4 | 962.82 Thousand USD | 2.66% |
| 2011 FY | 163.37 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 100.0% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 100.0% |
| Adocia SA | 2.15 Million EUR | 100.0% |
| Aelis Farma SA | 9.05 Million EUR | 100.0% |
| Biophytis S.A. | - EUR | NaN% |
| Advicenne S.A. | 3.15 Million EUR | 100.0% |
| genOway Société anonyme | 20.04 Million EUR | 100.0% |
| IntegraGen SA | 12.53 Million EUR | 100.0% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | 100.0% |
| Neovacs S.A. | 533.41 Thousand EUR | 100.0% |
| NFL Biosciences SA | - EUR | NaN% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 100.0% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | 100.0% |
| Sensorion SA | 4.74 Million EUR | 100.0% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | 100.0% |
| TME Pharma N.V. | 17 Thousand EUR | 100.0% |
| Valbiotis SA | 4.73 Million EUR | 100.0% |
| TheraVet SA | 1.07 Million EUR | 100.0% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 100.0% |
| Genfit S.A. | 28.56 Million EUR | 100.0% |
| GeNeuro SA | - EUR | NaN% |
| Innate Pharma S.A. | 51.9 Million EUR | 100.0% |
| Inventiva S.A. | 17.47 Million EUR | 100.0% |
| MaaT Pharma SA | 2.22 Million EUR | 100.0% |
| MedinCell S.A. | 9.16 Million EUR | 100.0% |
| Nanobiotix S.A. | 30.05 Million EUR | 100.0% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 100.0% |
| Poxel S.A. | 1.98 Million EUR | 100.0% |
| GenSight Biologics S.A. | 1.26 Million EUR | 100.0% |
| Transgene SA | 1.18 Million EUR | 100.0% |
| Valneva SE | 153.71 Million EUR | 100.0% |